Events Partner Content 9th Digital Pharma Europe The Digital Pharma Series in THE educational and networking choice for life science marketing innovators.
News J&J bids to extend prostate cancer uses for Akeega J&J is hoping the AMPLITUDE study results will make Akeega the first drug in the PARP inhibitor class for castration-sensitive prostate cancer.
Market Access The value of a partner, globally and locally A new podcast looks at recent trends related to drug approvals, as well as challenges and opportunities both small and large pharma companies face
